Recombinant Human LRRC32/GARP Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human LRRC32/GARP Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human LRRC32/GARP is immobilized at 5 μg/mL (100 μL/well) Recombinant Human Latent TGF‑ beta 1 (Catalog # 299-LT) binds with an apparent K_d <30 nM.
• Source: Chinese Hamster Ovary cell line, CHO-derived human LRRC32/GARP protein
  Met1-Asn627, with a C-terminal 6-His tag
• Accession #: Q14392
• N-terminal Sequence: Ala18
• Protein/Peptide Type: Recombinant Proteins
• Gene: LRRC32
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 67.0 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 70-80 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with trehalose..
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human LRRC32/GARP Protein, CF

• D11S833E
• D11S833Eleucine-rich repeat-containing protein 32
• GARP
• GARPGarpin
• Garpin
• Glycoprotein A repetitions predominantgarpin
• leucine rich repeat containing 32
• LRRC32

Background

Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant), is an 80 kDa type I transmembrane glycoprotein (1). Mature human LRRC32 consists of a 608 amino acid (aa) extracellular domain (ECD) that contains 22 leucine‑rich repeats, a 21 aa transmembrane segment, and a 14 aa cytoplasmic domain (2, 3). Within the ECD, human LRRC32 shares approximately 80% aa sequence identity with mouse and rat LRRC32. LRRC32 is widely expressed during embryogenesis and on adult platelets (4, 5). Human LRRC32 is identified as a lineage specific key receptor for human T cells. It is selectively expressed on activated FOXP3+ regulatory T cells (Treg) (6-10). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells (6 ‑ 8). LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells (9, 10). The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation (11).

1. Battaglia, M. and M.G. Roncarolo (2009) Eur. J. Immunol. 39:3296.
2. Ollendorff, V. et al. (1994) Cell Growth Differ. 5:213.
3. Bella, J. et al. (2008) Cell Mol Life Sci. 65:2307.
4. Roubin, R. et al. (1996) Int. J. Dev. Biol. 40:545.
5. Macaulay, I.C. et al. (2007) Blood 109:3260.
6. Wang, R. et al. (2008) PloS ONE 3:e2705.
7. Wang, R. et al. (2009) Proc. Natl. Acad. Sci. 106:13439.
8. Probst-Kepper, M. et al. (2009) J. Cell. Mol. Med. 13:3343.
9. Tran, D.Q. et al. (2009) Proc. Natl. Acad. Sci. 106:13445.
10. Stockis, J. et al. (2009) Eur. J. Immunol. 39:3315.
11. Vignali, D.A. et al. (2008) Nat. Rev. Immunol. 8:523.

Publications for LRRC32/GARP (6055-LR)(2)

Publications using 6055-LR

• Bellaye, PS;Dias, AM;Vrigneaud, JM;Bouchard, A;Moreau, M;Petitot, C;Bernhard, C;Claron, M;Froidurot, L;Morgand, V;Guillemin, M;Monterrat, M;Mirjolet, C;Garrido, C;Kohli, E;Collin, B; Targeted radionuclide therapy against GARP expressing T regulatory cells after tumour priming with external beam radiotherapy in a murine syngeneic model Heliyon 2024-10-30 [PMID: 39498075] (Bioassay, N/A)
• ER Trzeciak, N Zimmer, PW Kämmerer, D Thiem, B Al-Nawas, A Tuettenber, S Blatt GARP Regulates the Immune Capacity of a Human Autologous Platelet Concentrate Biomedicines, 2022-12-05;10(12):. 2022-12-05 [PMID: 36551892] (Western Blot, Human)

Bioinformatics

• Gene Symbol: LRRC32
• Uniprot:
  • Q14392()